Pipelines

01

DKD

Diabetic Kidney Disease (DKD) is a serious complication of diabetes, characterized by damage to the kidneys' filtering system, leading to a progressive decline in kidney function. It is a major cause of end-stage renal disease and increases the risk of cardiovascular events. Developing novel drugs to treat DKD, particularly those able to improve Glomerular Filtration Rate (GFR), requires addressing the complex pathophysiology of the disease. Our lead candidate, Cyclo-Z, has demonstrated a strong safety profile and promising preclinical data suggests its potential to improve GFR.

02

OBESITY

Some GLP-1 anti-obesity drugs raise concerns about muscle weakness/loss due to rapid weight reduction affecting both fat and lean mass, a greater concern in the elderly. This can lead to decreased strength and fatigue, impacting long-term metabolism and function. Preclinical studies with our compound, Cyclo-Z, show promise in improving muscle loss associated with certain GLP-1 drugs, suggesting a potential for a more balanced weight management approach when combined with them.

03

FSHD

Facioscapulohumeral muscular dystrophy (FSHD) is a progressive muscle-wasting disease with no FDA-approved treatments, creating an urgent need for novel therapies. Our lead candidate, CHP has shown promising results in preclinical in vivo studies, offering hope for addressing this unmet medical need.

04

DMD

Duchenne Muscular Dystrophy (DMD) is a severe, progressive genetic muscle-wasting disease. While some FDA-approved drugs exist, their efficacy in slowing disease progression remains limited, highlighting a significant need for novel and more effective therapies. Our lead candidate, CHP has demonstrated promising results in preclinical in vivo studies, suggesting its potential to address this critical unmet medical need in DMD.